Following close on the heels of the December 8, 2011 U.S. Food and Drug Administration advisory panel vote on Yaz/Yasmin/Beyaz, the FDA is planning a new panel to examine the question of whether all-metal hip implants, plagued by a high failure rate and other health concerns, should remain on the market.
The FDA panel on birth control has already voted that Beyaz, Yaz, and other contraceptives containing the compound drospirenone should remain on the market. But in the opinion of many ...
continue reading...